Invesaro

Stocks Comparison

Cencora vs NU Skin Enterprises: revenue, profit, margins and growth compared

Cencora brought in $321.3B of revenue in fiscal 2025, NU Skin Enterprises $1.5B in fiscal 2025. Revenue changed by +9.3% at Cencora and -14.3% at NU Skin Enterprises on the year before, so Cencora grew faster. Cencora kept 0.5% of its revenue as net profit, NU Skin Enterprises 10.8%. Free cash flow was $3.2B at Cencora and $46M at NU Skin Enterprises.

Side by side, latest fiscal year

CORNUS
Fiscal year endedFY2025 (September 30, 2025)FY2025 (December 31, 2025)
Revenue$321.3B$1.5B
Revenue growth+9.3%-14.3%
Net income$1.6B$160.2M
Net margin0.5%10.8%
Free cash flow$3.2B$46M
Free cash flow margin1.0%3.1%
Earnings per share (diluted)$7.96$3.18
Cash$4.4B$238.6M
Debt$7.7B$224.2M
Price to earnings38.61.5
Market value$58.6B$225.4M
Dividend yield0.72%n/a
Rank by revenue in sector#3 of 523 · Health care#122 of 523 · Health care

Over the years

Revenue
COR FY2018: $167.9BCOR FY2019: $179.6BCOR FY2020: $189.9BCOR FY2021: $214BCOR FY2022: $238.6BCOR FY2023: $262.2BCOR FY2024: $294BCOR FY2025: $321.3BNUS FY2018: $2.7BNUS FY2019: $2.4BNUS FY2020: $2.6BNUS FY2021: $2.7BNUS FY2022: $2.2BNUS FY2023: $2BNUS FY2024: $1.7BNUS FY2025: $1.5BFY18FY19FY20FY21FY22FY23FY24FY25
COR $321.3BNUS $1.5B
Net income
COR FY2018: $1.7BCOR FY2019: $855.4MCOR FY2020: -$3.4BCOR FY2021: $1.5BCOR FY2022: $1.7BCOR FY2023: $1.7BCOR FY2024: $1.5BCOR FY2025: $1.6BNUS FY2018: $121.9MNUS FY2019: $173.6MNUS FY2020: $191.4MNUS FY2021: $147.3MNUS FY2022: $104.8MNUS FY2023: $8.6MNUS FY2024: -$146.6MNUS FY2025: $160.2MFY18FY19FY20FY21FY22FY23FY24FY25
COR $1.6BNUS $160.2M
Net margin
COR FY2018: 1.0%COR FY2019: 0.5%COR FY2020: -1.8%COR FY2021: 0.7%COR FY2022: 0.7%COR FY2023: 0.7%COR FY2024: 0.5%COR FY2025: 0.5%NUS FY2018: 4.5%NUS FY2019: 7.2%NUS FY2020: 7.4%NUS FY2021: 5.5%NUS FY2022: 4.7%NUS FY2023: 0.4%NUS FY2024: -8.5%NUS FY2025: 10.8%FY18FY19FY20FY21FY22FY23FY24FY25
COR 0.5%NUS 10.8%
Revenue growth
COR FY2019: +6.9%COR FY2020: +5.7%COR FY2021: +12.7%COR FY2022: +11.5%COR FY2023: +9.9%COR FY2024: +12.1%COR FY2025: +9.3%NUS FY2019: -9.7%NUS FY2020: +6.7%NUS FY2021: +4.4%NUS FY2022: -17.4%NUS FY2023: -11.5%NUS FY2024: -12.0%NUS FY2025: -14.3%FY19FY20FY21FY22FY23FY24FY25
COR +9.3%NUS -14.3%
Free cash flow
COR FY2018: $1.1BCOR FY2019: $2BCOR FY2020: $1.8BCOR FY2021: $2.2BCOR FY2022: $2.2BCOR FY2023: $3.5BCOR FY2024: $3BCOR FY2025: $3.2BNUS FY2018: $132.4MNUS FY2019: $111.9MNUS FY2020: $315.3MNUS FY2021: $73MNUS FY2022: $49MNUS FY2023: $60.1MNUS FY2024: $70.2MNUS FY2025: $46MFY18FY19FY20FY21FY22FY23FY24FY25
COR $3.2BNUS $46M

Fiscal years as each company reports them; the two may end in different months.

Questions about Cencora and NU Skin Enterprises

Which is bigger by revenue, Cencora or NU Skin Enterprises?

Cencora is bigger by revenue: $321.3B in fiscal 2025, against $1.5B for NU Skin Enterprises in fiscal 2025.

Which keeps more of its revenue as profit, Cencora or NU Skin Enterprises?

Cencora had a net margin of 0.5% in fiscal 2025; NU Skin Enterprises had 10.8% in fiscal 2025.

Which grew revenue faster, Cencora or NU Skin Enterprises?

In their latest fiscal years revenue changed by +9.3% at Cencora and -14.3% at NU Skin Enterprises.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies